PhoreMost Awarded £1.4M Innovate UK Funding to Develop Lead Oncology Programme
Based on PhoreMost’s proprietary Protein Interference technology, the Company has developed ‘Site-Seeker’, a next-generation phenotypic screening platform that can identify the best new targets for drug development and, crucially, how to drug them. PhoreMost’s lead therapeutic programme has identified drug candidates to a novel synthetic-lethal target for KRAS. The Innovate UK funding will support development of this programme through phases of lead optimisation and candidate selection, with a longer aim to create a drug that may be tested in human clinical trials.
“We are pleased to receive funding from Innovate UK in support of our lead programme,” commented Dr Chris Torrance, CEO of PhoreMost. “The expert reviews conducted by Innovate UK provide independent, competitive validation of our lead programme development strategy, and the award funds will support our business aims to create novel therapies for cancer patients who have limited treatment options.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.